Refractory Chronic Cough Clinical Trial
— CORECOfficial title:
COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database
Verified date | May 2021 |
Source | University Hospital, Toulouse |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Chronic cough (TC), defined by a duration exceeding 8 weeks, is a particularly frequent symptom with a prevalence observed at 9.6% 1. Chronic cough is the cause of a major handicap for patients with a impact on their quality of life 2. Although CT is common, management is often delicate and complex. In studies, asthma, gastroesophageal reflux disease, posterior flushing, rhino-sinusitis, or taking tussigenic medications are common causes of chronic coughs. However, chronic refractory or unexplained cough, which corresponds to cough for which no cause has been found or the treatments directed against the cause of the cough have not made it possible to resolve the cough, is a real problem in practice. nick3. There is currently no prospective data in France on the characteristics of chronic cough (etiologies, response to treatment) and the percentage of refractory cough. The aim of the study is to constitute a French prospective multicenter hospital cohort of chronic cough patients in order to identify, for the first time in France in a prospective and multicenter manner, the frequency of patients with refractory cough among chronic cough patients.
Status | Active, not recruiting |
Enrollment | 576 |
Est. completion date | June 1, 2026 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age =18 years old - Consultation motivated by cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough) - Patient covered by a National Health Insurance Exclusion Criteria: - Active smoker or recent smoking cessation (within the past 6 months) - Intake of medications causing cough (the patient can be included 4 weeks after treatment discontinuation if cough persists) - Pregnant or breast-feeding women - Upper or lower respiratory tract infection within the past 4 weeks - Active lung disease (such as interstitial lung disease, lung cancer, abnormal dilation of the bronchi). - History of chronic bronchitis. - Current treatment with an angiotensin converting enzyme (ACE) inhibitor - History of cancer within the past 5 years or active cancer (excluding cutaneous squamous-cell carcinoma). - Person not fluent in French - Adult not able to express his/her consent verbally - Patient refusal |
Country | Name | City | State |
---|---|---|---|
France | UHToulouse | Toulouse |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Toulouse | MSD France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | French prospective multicenter hospital cohort of chronic cough patients (requency of patients with unexplained or refractory chronic cough (URCC) | set up a French prospective multicenter hospital cohort of chronic cough patients in order to identify the frequency of patients with unexplained or refractory chronic cough (URCC) for the first time in France | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282591 -
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
|
Phase 2 | |
Completed |
NCT03407014 -
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
|
Phase 2 | |
Completed |
NCT02476890 -
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
|
Phase 2 | |
Recruiting |
NCT05599191 -
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
|
Phase 3 | |
Recruiting |
NCT03662269 -
Indomethacin for Refractory Chronic Cough
|
Phase 3 | |
Recruiting |
NCT05962151 -
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
|
Phase 2 | |
Recruiting |
NCT05110144 -
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
|
Phase 2 | |
Enrolling by invitation |
NCT05733533 -
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
|
Phase 2 | |
Completed |
NCT02349425 -
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
|
Phase 2 | |
Recruiting |
NCT05600777 -
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
|
Phase 3 | |
Completed |
NCT05628740 -
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
|
Phase 1 | |
Not yet recruiting |
NCT06213363 -
A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough
|
Phase 1/Phase 2 | |
Completed |
NCT02412020 -
Treatment of Refractory Chronic Cough With PA101
|
Phase 2 | |
Completed |
NCT04678206 -
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
|
Phase 2 | |
Completed |
NCT02612623 -
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
|
Phase 2 | |
Completed |
NCT02612610 -
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
|
Phase 2 | |
Completed |
NCT02397460 -
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
|
Phase 2 | |
Not yet recruiting |
NCT05265871 -
ATP Level and Cough Sensitivity to ATP in Subjects With Refractory Chronic Cough
|